F-14/15, Orbit Mall, Civil Lines, Jaipur-302006
support@thetaxheaven.com
F-14/15, Orbit Mall, Civil Lines, Jaipur-302006 support@thetaxheaven.comHikal Ltd, a leading player in the pharmaceutical and crop protection industry, has made a significant mark in the Indian chemical sector. Known for its innovation, manufacturing excellence, and long-standing partnerships with global companies, Hikal continues to be a trusted name for investors seeking growth opportunities in specialty chemicals and pharma ingredients.
In this article, we’ll explore Hikal Ltd’s share price target from 2025 to 2030, analyze its business fundamentals, and discuss whether it can be a good long-term investment.
| Detail | Value |
|---|---|
| Open | ₹244.85 |
| Previous Close | ₹243.75 |
| High | ₹245.90 |
| Low | ₹242.25 |
| VWAP | ₹244.10 |
| Volume | 1,48,629 |
| Value (Lacs) | ₹362.88 |
| Beta (Volatility) | 0.88 |
| Market Capitalization | ₹3,010 Cr |
| 52-Week High | ₹464.75 |
| 52-Week Low | ₹236.20 |
| Face Value | ₹2 |
| All-Time High | ₹742.00 |
| All-Time Low | ₹6.36 |
Hikal’s share price has been under pressure due to recent challenges in the pharmaceutical sector, but the company’s solid fundamentals and diversified product portfolio offer long-term growth potential.
Founded in 1988, Hikal Ltd is an integrated manufacturer and supplier of active ingredients, intermediates, and specialty chemicals catering to the pharmaceutical, animal health, and crop protection industries.
With manufacturing facilities in Maharashtra and Gujarat, and long-term partnerships with global giants like Bayer, Syngenta, and Pfizer, Hikal continues to expand its footprint in regulated markets.
Strong presence in both pharma and agrochemical sectors
Long-term contracts with global clients ensuring business stability
Focused on R&D and sustainable manufacturing practices
Low beta (0.88) indicates lower volatility compared to market averages
Steady promoter holding of over 68% shows strong management confidence
| Investor Type | Holding (%) |
|---|---|
| Promoters | 68.85% |
| Retail & Others | 21.76% |
| Foreign Institutions | 4.23% |
| Mutual Funds | 4.09% |
| Other Domestic Institutions | 1.06% |
This stable shareholding pattern highlights consistent promoter confidence and increasing interest from institutional investors over the years.
| Year | Minimum Target (₹) | Maximum Target (₹) |
|---|---|---|
| 2025 | 250 | 265 |
| 2026 | 280 | 310 |
| 2027 | 320 | 355 |
| 2028 | 370 | 410 |
| 2029 | 420 | 470 |
| 2030 | 480 | 550 |
These price targets are based on Hikal’s business expansion, R&D pipeline, earnings growth, and the overall sectoral demand for pharma and agrochemical products.
By 2025, Hikal’s share is expected to remain stable as the company recovers from input cost pressures and focuses on export growth.
Why?
Stabilization in raw material costs
Steady demand in agrochemical exports
Strong promoter backing
Investment Advice: Good for short- to medium-term investors; accumulation near ₹240 levels may be beneficial.
In 2026, Hikal is expected to improve margins through efficiency gains and product diversification.
Why?
Higher capacity utilization at Taloja and Panoli plants
Expansion in regulated pharma markets
Strong order book visibility
Investment Advice: Ideal for long-term investors; potential for 10–12% annualized returns.
The company’s R&D-driven growth strategy and contract manufacturing expansion could lift profitability in 2027.
Why?
Growth in API and intermediates export
Rising demand from global pharmaceutical clients
Enhanced sustainability initiatives
Investment Advice: Reinvest dividends and maintain long-term holding for compounding growth.
By 2028, Hikal’s investments in green chemistry and automation are likely to yield significant cost benefits.
Why?
Adoption of AI and digital monitoring in production
Expansion of partnerships with agrochemical leaders
Improved debt-to-equity ratio
Investment Advice: Continue holding; expect consistent revenue growth with strong fundamentals.
In 2029, Hikal may strengthen its global presence in crop protection chemicals.
Why?
Growth in export demand for intermediates
New product launches in regulated markets
Diversification reducing dependency on few clients
Investment Advice: Strong buy for long-term portfolios; potential for above-market returns.
By 2030, Hikal could emerge as a leading integrated specialty chemical company from India with global relevance.
Why?
Continuous R&D investment
Strong brand credibility in global pharma supply chains
Sustained earnings growth and export-led expansion
Investment Advice: Excellent for long-term investors seeking stability, dividend income, and capital appreciation.
Yes, Hikal Ltd is a promising stock for long-term investors due to its strong promoter confidence, strategic global partnerships, and focus on innovation. The company’s dual presence in pharma and agrochemicals makes it resilient against sectoral downturns.
Strong promoter holding (68.85%)
Diversified revenue sources
Consistent R&D investment
Stable growth in export markets
Low beta, indicating steady performance
Fluctuations in raw material prices
Regulatory challenges in export markets
Competitive pressures from global peers
Always review quarterly results and company updates before investing.
Hikal Ltd stands as a well-managed company in India’s fast-growing pharma and agrochemical sectors. With a market capitalization of ₹3,010 crore and a strong order book, the company is positioned for steady long-term growth.
Currently trading around ₹244.85, Hikal’s share has the potential to reach ₹550 by 2030 if it continues on its current trajectory of operational efficiency, export expansion, and innovation.
For investors seeking a balanced combination of stability and long-term compounding, Hikal Ltd could be a smart addition to a diversified portfolio.
1. What is the next target of Hikal Ltd?
The next price target for Hikal Ltd is projected between ₹250 and ₹265 for 2025.
2. Is Hikal Ltd a good buy now?
Yes, at current levels near ₹245, Hikal offers good value for long-term investors.
3. What will be the future outlook of Hikal Ltd?
Hikal’s future looks promising with its focus on R&D, cost control, and export expansion.
4. What is the Hikal Ltd share price target for 2030?
By 2030, Hikal Ltd’s share price target is estimated between ₹480 and ₹550.
5. What is the 52-week high and low of Hikal Ltd?
The 52-week high is ₹464.75, and the 52-week low is ₹236.20.
6. Should I invest in Hikal Ltd for the long term?
Yes, it’s a strong long-term investment opportunity with steady financial growth potential.
Disclaimer: This article is for educational purposes only and does not constitute financial advice. Please consult a certified financial advisor before making investment decisions.
Register & Login